Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gain Therapeutics, Inc.GANX · Entity 6943 | Director | July 15, 2026 | July 17, 2026 |
| Theriva Biologics, Inc.SYN · Entity 7919 | Director · Chief Executive Officer | November 30, 2016 | December 02, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gain Therapeutics, Inc.
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2036-07-15 | Direct | 25,000 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.
Theriva Biologics, Inc.
Report date November 30, 2016 · Filed December 02, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2023-11-29 | Direct | 1,129,000 |
Reported balance
After 2016-11-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-11-30 · Grant · Acquired 1,129,000 · Balance 1,129,000 F1: These options will vest monthly on a pro rata basis over 36 consecutive months. |
Filing footnotes · ownership attribution and instrument terms
F1: These options will vest monthly on a pro rata basis over 36 consecutive months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 12:31 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001104659-26-084434 · tm2620629-2_4seq1.xml · derivative · entry 1 Riley Jeffrey Scott · CIK 0001487645 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-07-15 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| June 24, 2025 Filed Jun 25, 2025 21:30 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001641172-25-016540 · ownership.xml · derivative · entry 1 Riley Jeffrey Scott · CIK 0001487645 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2025, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| June 24, 2024 Filed Jun 27, 2024 01:30 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001493152-24-025337 · ownership.xml · derivative · entry 1 Riley Jeffrey Scott · CIK 0001487645 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2024, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:01 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | PurchaseCommon Stock | 30,000 | $3.86 | $115,770.00 |
DisclosureSEC source: 0001493152-24-012340 · ownership.xml · nonDerivative · entry 1 Riley Jeffrey Scott · CIK 0001487645 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.7098 to $3.924, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:39 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001209191-23-039725 · doc4.xml · derivative · entry 1 Riley Jeffrey Scott · CIK 0001487645 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2033-06-23 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 23, 2023, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:11 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-22-051011 · doc4.xml · derivative · entry 1 Riley Jeffrey Scott · CIK 0001487645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2032-09-20 F1 · derivative.exercise_date: The option vests fully on the day before the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 22:06 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 1,129,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001144204-16-137742 · v454263_4.xml · derivative · entry 1 Riley Jeffrey Scott · CIK 0001487645 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,129,000 Underlying: Common Stock · 1,129,000 shares Expires 2023-11-29 F1 · shares: These options will vest monthly on a pro rata basis over 36 consecutive months. F1 · derivative.exercise_date: These options will vest monthly on a pro rata basis over 36 consecutive months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.